» Articles » PMID: 11860403

Evaluation of Renal Function Following Treatment with 5-aminosalicylic Acid Derivatives in Patients with Ulcerative Colitis

Overview
Date 2002 Feb 28
PMID 11860403
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Background: A number of cases of nephrotoxicity have been reported in patients with inflammatory bowel disease taking oral 5-aminosalicylic acid (5-ASA).

Aim: To evaluate the effects of 9 months of therapy with mesalazine or olsalazine on renal function in patients with ulcerative colitis in remission.

Methods: Forty patients with ulcerative colitis in complete remission for 6 months were randomized to either olsalazine (n=20) or mesalazine (n=20 for nine months). Thirty-six of the 40 patients were on prior salicylate therapy. Disease activity was the measure ofclinical efficacy and was assessed by the Harvey-Bradshaw Index (HBI). Laboratory efficacy measurements included glomerular filtration rate (GFR), microalbuminuria, urinary gluthathione S-transferase (GST) and serum C-reactive protein (CRP). Safety analysis consisted of documentation of adverse events and laboratory values.

Results: There was no significant reduction in the GFR overall on therapy. The levels of GFR adjusted for baseline were similar in the two treatment groups after 3, 6 and 9 months. A significantly higher percentage of mesalazine-treated patients experienced drug related adverse events, all of a minor nature. The incidence of adverse events causing early withdrawal was similar in the two treatment groups.

Conclusion: Treatment with mesalazine or olsalazine for 9 months had no significant impact on GFR.

Citing Articles

Bioinformatics and systems biology approaches to identify molecular targeting mechanism influenced by COVID-19 on heart failure.

Yang K, Liu J, Gong Y, Li Y, Liu Q Front Immunol. 2022; 13:1052850.

PMID: 36420258 PMC: 9678344. DOI: 10.3389/fimmu.2022.1052850.


Prevalence of Renal Stones Among Patients With Inflammatory Bowel Disease in Saudi Arabia.

Mosli M, Alzahrani A, Bahafzalla R, Gazzaz T, Slaghour R, Altabsh G Cureus. 2021; 13(6):e15787.

PMID: 34295595 PMC: 8292829. DOI: 10.7759/cureus.15787.


Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.

Murray A, Nguyen T, Parker C, Feagan B, MacDonald J Cochrane Database Syst Rev. 2020; 8:CD000544.

PMID: 32856298 PMC: 8094989. DOI: 10.1002/14651858.CD000544.pub5.


AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis.

Singh S, Feuerstein J, Binion D, Tremaine W Gastroenterology. 2018; 156(3):769-808.e29.

PMID: 30576642 PMC: 6858923. DOI: 10.1053/j.gastro.2018.12.008.


Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses.

Nguyen N, Fumery M, Dulai P, Prokop L, Sandborn W, Murad M Lancet Gastroenterol Hepatol. 2018; 3(11):742-753.

PMID: 30122356 PMC: 6821871. DOI: 10.1016/S2468-1253(18)30231-0.